Showing results (471-480 of 512) with videos related to

Sort By:
Pageof 52
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 5, 2025
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction TreatmentRemo Panaccione, Marc Ferrante, Iris Dotan, et al.
Annals of Gastroenterology|March 5, 2020
Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experienceHajir Ibraheim, Mark A Samaan, Ashish Srinivasan, et al.
Alimentary Pharmacology & Therapeutics|June 20, 2022
A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centreSusanna Meade, Kamal V Patel, Raphael P Luber, et al.
Lancet (London, England)|June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E Sands, Peter M Irving, Timothy Hoops, et al.
Gut|September 3, 2020
Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panelRichard Hansen, Susanna Meade, R Mark Beattie, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Gastroenterology|April 29, 2015
Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal InflammationNick Powell, Jonathan W Lo, Paolo Biancheri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 19, 2016
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of ResultsGil Y Melmed, Peter M Irving, Jennifer Jones, et al.
Inflammatory Bowel Diseases|November 22, 2025
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by AgeAdam S Faye, David T Rubin, Corey A Siegel, et al.
Pageof 52